Skip to Main Content

Paper Details

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.
Neoplasia
22
2016
AR, AR(+), AR(+) CRPC models, AR(-) disease, AR(-) prostate cancer, AR(-) samples, CRPC, Castration-Resistant Prostate Cancer, HGF, MET, MET kinase, androgen, androgen receptor, cabozantinib, cancer, castration-resistant prostate cancer, enzalutamide, human, men, multiple AR, patients
Author NameAffiliation
Felix Y FengMichigan Center for Translational Pathology Department of Radiation Oncology Comprehensive Cancer Center.
Xuhong CaoMichigan Center for Translational Pathology Howard Hughes Medical Institute.
Nora M NavoneDepartment of Genitourinary Medical Oncology David H. Koch Center for Applied Research of Genitourinary Cancers.
David C SmithComprehensive Cancer Center Department of Internal Medicine.
Scott A TomlinsMichigan Center for Translational Pathology Department of Pathology Department of Urology Comprehensive Cancer Center.
Arul M ChinnaiyanMichigan Center for Translational Pathology Department of Pathology Department of Urology Howard Hughes Medical Institute Comprehensive Cancer Center. Electronic address: .
Arul M ChinnaiyanMichigan Center for Translational Pathology Department of Pathology Department of Urology Howard Hughes Medical Institute Comprehensive Cancer Center. Electronic address: .
Todd M MorganMichigan Center for Translational Pathology Department of Urology Comprehensive Cancer Center.
  • 1 - 8

Datasets

Release 1.2